Stay updated on Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.

Latest updates to the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has removed a notice about heavy traffic affecting certain services and the absence of posted results, while adding a confirmation that results have been submitted.SummaryDifference2%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check47 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check69 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.3%
- Check83 days agoChange DetectedThe study has expanded from 12 to 13 locations, now including Lanzhou, Gansu, China, with the latest update posted in December 2024.SummaryDifference2%
Stay in the know with updates to Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.